These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 27288608)
1. Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients. Dieplinger B; Egger M; Leitner I; Firlinger F; Poelz W; Lenz K; Haltmayer M; Mueller T J Crit Care; 2016 Aug; 34():38-45. PubMed ID: 27288608 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit - The Linz Intensive Care Unit (LICU) study. Dieplinger B; Egger M; Koehler W; Firlinger F; Poelz W; Lenz K; Haltmayer M; Mueller T Clin Chim Acta; 2012 Mar; 413(5-6):587-93. PubMed ID: 22155704 [TBL] [Abstract][Full Text] [Related]
3. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080 [TBL] [Abstract][Full Text] [Related]
4. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of low interleukin-33 in critically ill patients. Krychtiuk KA; Stojkovic S; Lenz M; Brekalo M; Huber K; Wojta J; Heinz G; Demyanets S; Speidl WS Cytokine; 2018 Mar; 103():109-113. PubMed ID: 28974430 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996 [TBL] [Abstract][Full Text] [Related]
7. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients. Obokata M; Sunaga H; Ishida H; Ito K; Ogawa T; Ando Y; Kurabayashi M; Negishi K Am Heart J; 2016 Sep; 179():29-41. PubMed ID: 27595677 [TBL] [Abstract][Full Text] [Related]
8. ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population. Rudolf JW; Lewandrowski EL; Lewandrowski KB; Januzzi JL; Bajwa EK; Baron JM Am J Clin Pathol; 2016 Feb; 145(2):203-10. PubMed ID: 26857195 [TBL] [Abstract][Full Text] [Related]
9. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847 [TBL] [Abstract][Full Text] [Related]
10. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2. Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580 [TBL] [Abstract][Full Text] [Related]
11. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Maksym J; Balsam P; Opolski G; Filipiak KJ Pol Arch Intern Med; 2019 Nov; 129(11):770-780. PubMed ID: 31642446 [TBL] [Abstract][Full Text] [Related]
12. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907 [TBL] [Abstract][Full Text] [Related]
14. Prognostic values of novel biomarkers in patients with AL amyloidosis. Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944 [TBL] [Abstract][Full Text] [Related]
15. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511 [TBL] [Abstract][Full Text] [Related]
17. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Zhang K; Zhang XC; Mi YH; Liu J Chin Med J (Engl); 2013; 126(19):3628-31. PubMed ID: 24112154 [TBL] [Abstract][Full Text] [Related]